ClinicalTrials.gg
RecruitingNCT05898477Updated Jan 22, 2026

Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis

An observational study in Lymphoma and Hemophagocytic Lymphohistiocytoses, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by University of Alabama at Birmingham · Observational

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
2,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,910 studies in Lymphoma with a site in United States — 161 open to participants now, 288 under way, 15 of them phase 3. Lymphoma · United States.

Planned enrollment
17th of 160
2,000 · median 120
Started
2023
with 41 others
Observational
160 of 1,910
31 open now
Primary completion
2028-01
later than 187 of 281 live
Registered
1,785th of 1,910
by date

Among the 1,910 studies in Lymphoma with a site in United States, this one is the 17th largest by planned enrollment of the 160 observational ones that give a count, is one of 42 that started in 2023, is one of 160 observational ones, reaches primary completion later than 187 of the 281 other live ones, and was the 1,785th registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

Browse Lymphoma studies →

Open to participants now

161 of the 1,910 studies in Lymphoma with a site in United States are open now. Recruiting first, the newest first:

156 more — sign in →

All 161 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,910 studies in Lymphoma with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in patients with lymphoma to identify possible therapeutic strategies to improve overall survival of the patients with lymphoma associated hemophagocytic lymphohistiocytosis.

Read the detailed description

Retrospective, multi-institutional study focused on describing the clinical features, laboratory parameters, treatments, and outcomes among individuals presenting with HLH in the setting of a lymphoma

03

Conditions studied

  • Lymphoma
  • Hemophagocytic Lymphohistiocytoses
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with diagnosis of Hemophagocytic lymphohistiocytosis (HLH)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with lymphoma that are fulfilling at least one of the following:

A. Meeting 5 of 8 HLH-2004 diagnostic criteria OR B. Are OHI index positive (sCD25>3,900 U/mL and ferritin>1,000 ng/mL)

Exclusion criteria

Exclusion Criteria:

  • Patients developing HLH> 1 month after lymphoma diagnosis (for aggressive lymphomas)
  • Patients with incomplete treatment and response documentation
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
2,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Hemophagocytic lymphohistiocytosis (HLH) Patients
06

What researchers measure

Primary outcomes

  1. To determine the factors predicting 180 days overall survival of patients with cancer that are HLH-2004/OHI+

    The investigators will gather data on different treatments received, time to treatment, and other factors and determine which is associated with survival.

    Time frame: The participant's survival would be assessed at 180 days from the malignancy diagnosis

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2023 (actual). Primary completion is estimated for Jan 2028, 56 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2023
First posted
Jun 12, 2023
StartActual
May 1, 2023
Primary completionEst.
Jan 2028
CompletionEst.
Jul 2028
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05898477
Responsible party
Gaurav Goyal (Principal Investigator, University of Alabama at Birmingham) — Principal investigator
First posted
Jun 12, 2023
Start date
May 1, 2023
Primary completion
Jan 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Jan 22, 2026

Study contacts

Gaurav Goyal, MD
Contact
ggoyal@uabmc.edu
205-934-1816
Gaurav Goyal, MD
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion